Estrogen, Probiotics and Vaginal Health to Prevent HIV Infection in ACB Women

NCT ID: NCT03837015

Last Updated: 2021-12-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-11-04
• Study Completion Date: 2021-12-14

Brief Summary

This study will enrol African, Caribbean and Black (ACB) women who are known to have a more diverse vaginal microbiome, higher rates of bacterial vaginosis with lower numbers of protective lactobacilli, and are at increased risk for HIV. The investigators will evaluate the safety, feasibility, effect on the vaginal bacterial microbiome and changes in local immune and inflammatory responses with the administration of vaginal estrogen alone, vaginal estrogen in combination with oral or vaginally administered probiotics, or vaginal probiotics alone.

Detailed Description

Women are at increased risk of HIV acquisition compared with men. A number of biological factors are associated with increased risk, many of which likely enhance risk by increasing inflammation in the female genital tract. Susceptibility to infections and immune responses in the female genital tract are regulated by hormones: progesterone increases inflammation and HIV susceptibility and estrogen decreases inflammation and enhances colonization with Lactobacilli.

A Lactobacillus dominant vaginal microbiome is associated with increased protection against HIV, while a polymicrobial vaginal flora, as seen in bacterial vaginosis, is associated with increased risk. About 40% of ACB women have a polymicrobial flora.

The goal of this study is to establish a Lactobacillus dominant vaginal microbiome in ACB women, that will be associated with decreased inflammation and decreased susceptibility to HIV, by administering a low level of intravaginal estrogen to increase colonization with Lactobacilli together with a Lactobacillus-containing probiotic.

Conditions

HIV-1-infection; Bacterial Vaginoses

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Estring alone

Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention.

Group Type: ACTIVE_COMPARATOR

Estring Vaginal Ring

Intervention Type: DRUG

Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days

Estring and vaginal RepHresh Pro-B

Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention. Participants will also be instructed to insert one RepHresh Pro-B capsule vaginally twice daily, morning and night, until day 30

Group Type: ACTIVE_COMPARATOR

Estring Vaginal Ring

Intervention Type: DRUG

Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days

RepHresh Pro-B

Intervention Type: OTHER

Probiotic supplement containing 2.5 billion CFU of Lactobacilli reuteri RC-14 and Lactobacilli rhamnosus GR-1, administered vaginally or orally

Estring and oral RepHresh Pro-B

Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention. Participants will be instructed to take one RepHresh Pro-B capsule orally twice daily until day 30.

Group Type: ACTIVE_COMPARATOR

Estring Vaginal Ring

Intervention Type: DRUG

Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days

RepHresh Pro-B

Intervention Type: OTHER

Probiotic supplement containing 2.5 billion CFU of Lactobacilli reuteri RC-14 and Lactobacilli rhamnosus GR-1, administered vaginally or orally

Vaginal RepHresh Pro-B

Participants will be given a 30 days supply of RepHresh Pro-B and instructed to insert one capsule vaginally twice daily until day 30.

Group Type: ACTIVE_COMPARATOR

RepHresh Pro-B

Intervention Type: OTHER

Probiotic supplement containing 2.5 billion CFU of Lactobacilli reuteri RC-14 and Lactobacilli rhamnosus GR-1, administered vaginally or orally

Interventions

Estring Vaginal Ring

Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days

Intervention Type: DRUG

RepHresh Pro-B

Probiotic supplement containing 2.5 billion CFU of Lactobacilli reuteri RC-14 and Lactobacilli rhamnosus GR-1, administered vaginally or orally

Intervention Type: OTHER

Other Intervention Names

17 beta-estradiol

Eligibility Criteria

Inclusion Criteria

• African, Caribbean, Black
• Pre-menopausal women in good general health, as determined by the investigator
• Uterus and cervix present
• Negative pregnancy test
• Currently practicing barrier or non-hormonal forms of contraception, and planning to continue, for the duration of the study (barrier contraceptive, abstinence)
• Willing to undergo a pelvic exam by a female nurse/female doctor
• Willing to abstain from vaginal intercourse for 48 hours prior to sampling, over the entire course of the study
• Able to understand, comply and consent to protocol requirements and instructions
• Able to attend scheduled study visits and complete required investigations

Exclusion Criteria

• Currently lactating
• Pregnant: suspected, current or in the last 12 months
• Irregular menstrual cycle (less than 6 periods in a year) not related to contraceptive use, pregnancy or breastfeeding
• Post-menopausal
• Hormonal Contraceptive use or other hormonal treatment in the past 3 months
• Current Intra-Uterine Device (IUD) use
• Positive test result for Gonorrhea and/or Chlamydia
• Clinically obvious genital ulceration/lesions
• Symptomatic vaginal yeast infection or clinically significant vaginal discharge
• HIV-positive
• Any clinically significant abnormality on screening safety blood tests, that in the opinion of the investigator would preclude enrolment.
• Diagnosed blood clotting disorder
• Any genital tract procedure (e.g. biopsy) within the past 6 months
• Use of oral probiotic supplement, oral antibiotics or oral steroids within the past 30 days
• Current use of any vaginal products (except tampons) such as spermicides, microbicides, douching or drying products, antifungals, or steroids.
• Known intolerance of Lactobacillus-containing probiotic supplements
• Undiagnosed abnormal genital bleeding
• Known, suspected, or history of breast cancer
• Known or suspected estrogen-dependent malignant neoplasia (e.g. endometrial cancer)
• Currently taking immunosuppressive drugs
• Known or suspected hypersensitivity to any component of the Estring or RepHresh Pro-B products
• Diagnosis of endometrial hyperplasia
• Known liver dysfunction or disease; as long as liver function tests have failed to return to normal
• Active or past history of arterial thromboembolic disease (e.g. stroke, myocardial infarction, coronary heart disease)
• Partial or complete loss of vision due to ophthalmic vascular disease
• Porphyria
• Concomitant medication which in the opinion of the investigator may be associated with a significant drug interaction with the estrogen in Estring.
• The conditions below are grounds for exclusion based on the opinion of the investigator:

1. Risk factors for estrogen dependent tumours, e.g. first degree heredity for breast cancer

2. Diabetes mellitus with or without vascular involvement

3. Migraine or (severe) headache

4. Epilepsy

5. A history of, or risk factors for, thromboembolic disorders

6. Systemic lupus erythematosus

7. Otosclerosis

8. Cholelithiasis

9. Leiomyoma (uterine fibroids)

10. Endometriosis

11. A history of endometrial hyperplasia

12. Hypertension

13. Asthma

14. Diagnosed anemia

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 49 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

CIHR Canadian HIV Trials Network

NETWORK

Sponsor Role: collaborator

McMaster University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Women's Health in Women's Hands

Toronto, Ontario, Canada

Countries

Canada

References

Gill B, Wessels JM, Hayes CL, Ratcliffe J, Wokuri J, Ball E, Reid G, Kaul R, Rana J, Alkhaifi M, Tharao W, Smaill F, Kaushic C. Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial. PLoS One. 2025 Jan 21;20(1):e0315576. doi: 10.1371/journal.pone.0315576. eCollection 2025.

Reference Type: DERIVED

PMID: 39836666 (View on PubMed)

Other Identifiers

CTN308

Identifier Type: -

Identifier Source: org_study_id